1
Antiviral Drugs for Seasonal Influenza
The Medical Letter on Drugs and Therapeutics • November 9, 2026; (Issue 1767)
Influenza is typically a self-limited illness, but complications
including pneumonia, respiratory failure, and death can
occur, especially in persons at increased risk (see Table 1).
Influenza vaccination reduces the incidence of laboratory-confirmed influenza and the risk of complications associated
with influenza illness. Annual vaccination should be offered
to all persons ≥6 months old as long as influenza viruses are
circulating in the community.
2
2026-2027 COVID-19 Vaccination
The Medical Letter on Drugs and Therapeutics • October 26, 2026; (Issue 1766)
The FDA has licensed 2026-2027 formulas of the mRNA
COVID-19 vaccines Comirnaty, Spikevax, and mNEXSPIKE
and the adjuvanted protein subunit COVID-19 vaccine
Nuvaxovid.
3
Comparison Chart: Antiviral Drugs for Seasonal Influenza (online only)
The Medical Letter on Drugs and Therapeutics • November 9, 2026; (Issue 1767)
View the Comparison Chart: Antiviral Drugs for Seasonal Influenza
4
Seasonal Influenza Vaccination: 2026-2027
The Medical Letter on Drugs and Therapeutics • October 12, 2026; (Issue 1765)
Annual influenza vaccination is recommended for all persons
≥6 months old without a contraindication. Influenza
vaccines available this season in the US are listed in Table 3.
5
In Brief: An Expanded Indication for Afrezza
The Medical Letter on Drugs and Therapeutics • October 26, 2026; (Issue 1766)
The rapid-acting inhaled human insulin Afrezza (MannKind),
which was approved in 2014 for treatment of type 1 or type
2 diabetes in adults, has now been approved by the FDA for
use in children ≥6 years old.
6
A New Indication for Finerenone (Kerendia)
The Medical Letter on Drugs and Therapeutics • November 23, 2026; (Issue 1768)
The FDA has approved the nonsteroidal mineralocorticoid
receptor antagonist (MRA) finerenone (Kerendia) to reduce
the urinary albumin-to-creatinine ratio (UACR) in adults
with chronic kidney disease (CKD) associated with type 1
diabetes. Reducing UACR is expected to reduce the risk
of sustained eGFR decline and progression to end-stage
kidney disease. Finerenone is the first drug to be approved
in the US for this indication in 30 years.
7
In Brief: Statins for Primary Prevention in Older Adults
The Medical Letter on Drugs and Therapeutics • November 23, 2026; (Issue 1768)
HMG-CoA reductase inhibitors (statins) are the drugs of
choice for lowering low-density lipoprotein cholesterol
(LDL-C). They reduce the risk of primary and secondary
atherosclerotic cardiovascular disease (ASCVD) events and
death, but data supporting their efficacy and safety in older
adults have been lacking. Guidelines recommend weighing
the potential risks and benefits when deciding whether to
start or stop statin therapy for primary prevention in adults
>75 years old. Results of a trial evaluating statin initiation
for primary prevention of ASCVD in older persons have
recently been published.
8
Tavapadon (Juvmo) for Parkinson's Disease
The Medical Letter on Drugs and Therapeutics • November 9, 2026; (Issue 1767)
Tavapadon (Juvmo – Abbvie), an oral nonergot partial
dopamine agonist, has been approved by the FDA for
treatment of Parkinson's disease (PD).
9
In Brief: New Warning for GLP-1 Receptor Agonists
The Medical Letter on Drugs and Therapeutics • November 16, 2026; (Issue 5135)
The FDA is requiring that a warning about a risk of
nonarteritic anterior ischemic optic neuropathy (NAION) be
added to the package inserts of the GLP-1 receptor agonists
dulaglutide (Trulicity), exenatide, liraglutide (Saxenda,
Victoza), semaglutide (Ozempic, Rybelsus, Wegovy), and
orforglipron (Foundayo) and the dual glucose-dependent
insulinotropic polypeptide (GIP)/GLP-1 receptor agonist
tirzepatide (Mounjaro, Zepbound).
10
Treatment of Allergic Rhinitis and Allergic Conjunctivitis
The Medical Letter on Drugs and Therapeutics • March 31, 2025; (Issue 1725)
Initial treatment of allergic rhinitis (AR) depends
on the severity of symptoms and whether they are
intermittent or persistent (see Table 1).
